Oruka Therapeutics (ORKA) Competitors $20.42 -1.78 (-8.02%) (As of 10:45 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends ORKA vs. VNRX, OCX, ICCC, AWH, TRIB, VRAX, CDIO, BMRA, TNFA, and MYMDShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include VolitionRx (VNRX), OncoCyte (OCX), ImmuCell (ICCC), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Virax Biolabs Group (VRAX), Cardio Diagnostics (CDIO), Biomerica (BMRA), TNF Pharmaceuticals (TNFA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry. Oruka Therapeutics vs. VolitionRx OncoCyte ImmuCell Aspira Women's Health Trinity Biotech Virax Biolabs Group Cardio Diagnostics Biomerica TNF Pharmaceuticals MyMD Pharmaceuticals Oruka Therapeutics (NASDAQ:ORKA) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in ORKA or VNRX? 56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by insiders. Comparatively, 12.8% of VolitionRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer ORKA or VNRX? Oruka Therapeutics received 7 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 100.00% of users gave Oruka Therapeutics an outperform vote while only 10.53% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformOruka TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesVolitionRxOutperform Votes410.53%Underperform Votes3489.47% Which has higher earnings and valuation, ORKA or VNRX? Oruka Therapeutics has higher earnings, but lower revenue than VolitionRx. Oruka Therapeutics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$5.34M-$6.26-3.26VolitionRx$770K97.48-$35.32M-$0.36-2.25 Which has more volatility and risk, ORKA or VNRX? Oruka Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Is ORKA or VNRX more profitable? Oruka Therapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -24.96% -21.22% VolitionRx -2,321.14%N/A -163.39% Does the media refer more to ORKA or VNRX? In the previous week, Oruka Therapeutics had 21 more articles in the media than VolitionRx. MarketBeat recorded 26 mentions for Oruka Therapeutics and 5 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.53 beat Oruka Therapeutics' score of -0.05 indicating that VolitionRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral VolitionRx 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ORKA or VNRX? Oruka Therapeutics currently has a consensus price target of $43.17, suggesting a potential upside of 111.39%. VolitionRx has a consensus price target of $2.50, suggesting a potential upside of 208.64%. Given VolitionRx's higher probable upside, analysts clearly believe VolitionRx is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13VolitionRx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryOruka Therapeutics beats VolitionRx on 11 of the 18 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.71M$2.21B$5.08B$8.80BDividend YieldN/A0.75%5.02%4.07%P/E Ratio-3.263.9191.2813.60Price / SalesN/A40.841,226.2187.40Price / CashN/A14.8239.4536.27Price / Book0.073.076.906.33Net Income-$5.34M$29.98M$118.83M$225.93M7 Day Performance-14.92%-1.67%-1.92%-0.96%1 Month Performance-33.03%-10.46%-3.75%1.06%1 Year PerformanceN/A-15.85%31.37%26.59% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics3.7074 of 5 stars$20.42-8.0%$43.17+111.4%N/A$24.71MN/A-3.26N/AAnalyst ForecastAnalyst RevisionGap UpVNRXVolitionRx1.4643 of 5 stars$0.81flat$2.50+208.6%+10.9%$75.06M$770,000.000.0080Analyst ForecastOCXOncoCyte1.4353 of 5 stars$2.80+1.8%$4.42+57.7%-32.8%$47.12M$1.50M0.00120Analyst ForecastICCCImmuCell0.5144 of 5 stars$3.57-0.8%N/A-22.1%$31.81M$17.47M-7.2075AWHAspira Women's Health1.533 of 5 stars$0.70-3.8%$4.40+526.4%-78.5%$11.28M$9.15M-0.64110Analyst ForecastTRIBTrinity Biotech1.8087 of 5 stars$1.32+1.5%N/A-33.5%$10.06M$56.83M-0.58480Gap DownVRAXVirax Biolabs Group0.2721 of 5 stars$1.84-2.1%N/A-24.8%$5.94M$160,000.000.005CDIOCardio Diagnostics2.1281 of 5 stars$0.24-3.1%$2.00+745.0%-89.0%$5.67M$20,000.000.007BMRABiomericaN/A$0.33+2.8%N/A-64.4%$5.61M$5.41M-0.8860News CoverageGap DownTNFATNF PharmaceuticalsN/A$1.19-3.3%N/AN/A$3.28MN/A0.006MYMDMyMD PharmaceuticalsN/A$1.23+7.0%N/A-87.3%$2.92MN/A0.009 Related Companies and Tools Related Companies VNRX Competitors OCX Competitors ICCC Competitors AWH Competitors TRIB Competitors VRAX Competitors CDIO Competitors BMRA Competitors TNFA Competitors MYMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORKA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORKA Stock Alerts